(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Tuberous Sclerosis Clinic at Cincinnati Children's is home to specialists with a variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child's unique needs.
David Neal Franz, MD Founding Director, Tuberous Sclerosis Clinic 513-636-4222 email@example.com
Founding Director, Tuberous Sclerosis Clinic
Associate Director of Clinical Affairs, Division of Neurology
Professor, UC Department of Pediatrics
David Neal Franz, MD, was born and raised in Dayton, Ohio. He received his undergraduate degree in history and literature from Earlham College in Richmond, Indiana.
After completing his training, he served as assistant professor of neurology and pediatrics at Wright State University before returning to Cincinnati Children's Hospital Medical Center.
He established the Cincinnati Tuberous Sclerosis Clinic in 1993, to assist in the medical care of patients who have or are suspected of having tuberous sclerosis. The purpose of the clinic is not to replace care from the child's pediatrician or family physician, but to assist the primary care physician in dealing with those aspects unique to tuberous sclerosis that affect the child's health or development. The basis of the clinic is the realization that people with tuberous sclerosis are different from other individuals who have epilepsy, learning disabilities, behavior problems, etc.
For too long, the unique problems found in this disease have been lumped together with similar disorders, despite the fact that research has shown that disorders of the brain, heart, kidney, and other organs in tuberous sclerosis are quite different.
MD: Ohio State University College of Medicine, Columbus, OH, 1985.
Residency: Wright State University Affiliated Hospitals, Dayton, OH.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 1990, 2014; Neurology with special competence in child neurology, 1992.
Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010 Oct;41(5):199-208.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11.
Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674-81.
Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.
Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, Dardzinski BJ, Brody AS. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJR Am J Roentgenol. 2009 Apr;192(4):1037-44.
Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313. Review.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):140-51.
Levine NB, Collins J, Franz DN, Crone KR. Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg. 2006 Oct;49(5):317-20.
Collins JJ, Tudor C, Leonard JM, Chuck G, Franz DN. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006 Jan;21(1):53-7.
Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar;59(3):490-8.
Darcy A. Krueger, MD, PhD Director, Tuberous Sclerosis Clinic 513-636-4222 firstname.lastname@example.org
Director, Tuberous Sclerosis Clinic
Associate Professor, UC Department of Pediatrics
Tuberous sclerosis; general neurology
MD: Saint Louis University School of Medicine, St. Louis, MO, 1995-1997; 2000-2002.
PhD: Saint Louis University Graduate School Biochemistry and Molecular Biology, St. Louis, MO, 1997-2000.
Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure. 2011 Apr;20(3):266-70.
Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313.
Jamie K. Capal, MD Pediatric Neurologist, Division of Neurology 513-636-4222 email@example.com
Pediatric Neurologist, Division of Neurology
Assistant Professor, UC Department of Pediatrics
Child neurology; developmental pediatrics; autism; tuberous sclerosis
Dr. Capal’s clinical and research interests focus on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but not always with concurrent clinical seizures. A natural extension of her research has led to interest in tuberous sclerosis complex (TSC), where autism, abnormal EEG, and seizures are frequent and interdependent. The genetic and molecular basis of TSC is well established, which provides an ideal platform for further investigation into the underlying mechanisms responsible and, in turn, discover new molecular-based targeted therapies. The TSC Clinic at Cincinnati Children’s Hospital Medical Center is the largest of its kind in the world, providing comprehensive, multidisciplinary clinical care to TSC patients of any age. This work led efforts that resulted in the first ever FDA-approved medical therapy for TSC in 2010 using the mTOR inhibitor everolimus. The long-term goal is to refine and apply these and next-generation therapies for patients with TSC.
BA: Biology with honors, Ithaca College, Ithaca, NY, 2002.
MD: Albany Medical College, Albany, NY, 2002.
Internship: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2006-2007.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.
Resident/Fellow: Pediatric Neurodevelopmental Disabilities, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008-1012.
Jens W. Goebel, MD Clinical Director, Nephrology and Hypertension 513-636-4531 firstname.lastname@example.org
Clinical Director, Nephrology and Hypertension
Medical Director, Kidney Transplantation
Clinical Director, Kidney Transplantation
Organ transplantation in children
MD: University of Heidelberg (Germany), 1991.
Residency and Chief Residency: Department of Pediatrics, University of South Alabama, Mobile, AL, 1991 to 1995.
Fellowship: Section of Pediatric Nephrology, Tulane University Medical Center, New Orleans, LA, 1995 to 1998.
Certifications: General Pediatrics, 1994, 2002; Pediatric Nephrology, 1999.
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7.
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.
Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, Martz K, Bucuvalas J; SPLIT Renal Function Working Group. Glomerular filtration rate following pediatric liver transplantation--the SPLIT experience. Am J Transplant. 2010 Dec;10(12):2673-82.
Pai AL, Gray E, Kurivial K, Ross J, Schoborg D, Goebel J. The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens. Pediatr Transplant. 2010 Dec;14(8):993-9.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Pai AL, Ingerski LM, Perazzo L, Ramey C, Bonner M, Goebel J. Preparing for transition? The allocation of oral medication regimen tasks in adolescents with renal transplants. Pediatr Transplant. 2011 Feb;15(1):9-16.
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Herzer M, Goebel J, Cortina S. Transitioning cognitively impaired young patients with special health needs to adult-oriented care: collaboration between medical providers and pediatric psychologists. Curr Opin Pediatr. 2010 Oct;22(5):668-72.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
Stuart L. Goldstein, MD, FAAP, FNKF Director, Center for Acute Care Nephrology 513-803-3295 email@example.com
Director, Center for Acute Care Nephrology
Medical Director, Pheresis Service
Co-Medical Director, Heart Institute Research Core
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.
Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010–Dec 2020.
Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Gambro Renal Products. Nov 2011-Jan 2017.
Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2016.
Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Casey Lee Ball Foundation. Feb 2013–Jun 2015.
An Observational, Genomic Study of Patients with Drug Induced Kidney Injury. Principal Investigator. International SAE Consortium, LTD. May 2013-Dec 2015.
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. NICHD Pediatric Trials Network-POPS. Feb 2013–Feb 2017.
Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP Trial). Principal Investigator. NICHD-2013-ABS01 Pediatric Trials Network. May 2014–Sep 2017.
Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.
Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.
Elizabeth S. Gosnell, DMD, MS Pediatric Dentist, Division of Pediatric Dentistry 513-636-4641 firstname.lastname@example.org
Pediatric Dentist, Division of Pediatric Dentistry
Craniofacial Anomalies Team Dentist
DMD: Medical University of South Carolina, Charleston, SC, 2009.
Residency: Pediatric Dentistry, Nationwide Children's Hospital, Columbus, OH, 2011.
MS: The Ohio State University, Columbus, OH, 2011.
Timothy K. Knilans, MD Director, Clinical Cardiac Electrophysiology and Pacing 513-636-7269 email@example.com
Director, Clinical Cardiac Electrophysiology and Pacing
Cardiac electrophysiology and pacing; radio frequency ablation; tilt table testing
MD: University of Cincinnati, Cincinnati, OH, 1983.
Residency: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1983-1986.
Fellowship (Pediatric Cardiology): Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1986-1989.
Fellowship (Cardiac Electrophysiology): St. Vincent Hospital, Indianapolis, IN, 1990-1991.
Fellowship (Pediatric cardiac Electrophysiology): Texas Children's Hospital, Houston, TX, 1991.
Certification: Pediatrics, 1989 (Recertified 1999); Pediatric Cardiology, 1992 (Recertified 1998).
Czosek RJ, Anderson JB, Marino BS, Mellion K, Knilans TK. Noninvasive risk stratification techniques in pediatric patients with ventricular preexcitation. Pacing Clin Electrophysiol. 2011 May;34(5):555-62.
Eghtesady P, Michelfelder EC, Knilans TK, Witte DP, Manning PB, Crombleholme TM. Fetal surgical management of congenital heart block in a hydropic fetus: Lessons learned from a clinical experience. J Thorac Cardiovasc Surg. 2011 Mar;141(3):835-7.
Czosek RJ, Anderson J, Marino BS, Connor C, Knilans TK. Linear lesion cryoablation for the treatment of atrioventricular nodal re-entry tachycardia in pediatrics and young adults. Pacing Clin Electrophysiol. 2010 Nov;33(11):1304-11.
Czosek RJ, Anderson JB, Cao J, Knilans TK. Assessment of T-wave oversensing in an infant with an implanted defibrillator. Heart Rhythm. 2010 Oct;7(10):1516-7.
Mays WA, Border WL, Knecht SK, Gerdes YM, Pfriem H, Claytor RP, Knilans TK, Hirsch R, Mone SM, Beekman RH 3rd. Exercise capacity improves after transcatheter closure of the Fontan fenestration in children. Congenit Heart Dis. 2008 Jul;3(4):254-61.
Knecht SK, Mays WA, Gerdes YM, Claytor RP, Knilans TK. Exercise evaluation of upper- versus lower-extremity blood pressure gradients in pediatric and young-adult participants. Pediatr Exerc Sci. 2007 Aug;19(3):344-8.
Wright KN, Knilans TK, Irvin HM. When, why, and how to perform cardiac radiofrequency catheter ablation. J Vet Cardiol. 2006 Nov;8(2):95-107.
Knilans TK. Multielectrode coronary artery catheterization: still an effective tool in ablation of right free-wall accessory pathways. J Cardiovasc Electrophysiol. 2004 Nov;15(11):1244-5.
Markham LW, Knecht SK, Daniels SR, Mays WA, Khoury PR, Knilans TK. Development of exercise-induced arm-leg blood pressure gradient and abnormal arterial compliance in patients with repaired coarctation of the aorta. Am J Cardiol. 2004 Nov 1;94(9):1200-2.
Beery TA, Dyment M, Shooner K, Knilans TK, Benson DW. A candidate locus approach identifies a long QT syndrome gene mutation. Biol Res Nurs. 2003 Oct;5(2):97-104.
Daniel A. Nelson, MD Medical Director, Child Psychiatry Unit 513-636-4788 firstname.lastname@example.org
Medical Director, Child Psychiatry Unit
Inpatient and outpatient child psychiatry diagnosis, treatment and research; bipolar and mood disorders; attention deficit hyperactivity disorder; childhood trauma; behavioral disorders
Dr. Nelson is a recognized authority in counseling children and families who have experienced trauma -- from natural and man-made disasters to abuse. After the September 11th attacks in New York City, Nelson, along with other psychiatrists and psychologists, provided assistance to many victims' families.
In addition, Dr. Nelson supervised the Family Notification Center after the Oklahoma City bombing, which he designed to provide comprehensive psychological support to minimize the effects of trauma in that city. Nelson, who directs the inpatient child psychiatric unit at Cincinnati Children's Hospital Medical Center, also provides training and education in response to trauma. In 1999, he worked with teachers and counselors following a tornado that killed four people in the Cincinnati area and destroyed dozens of homes.
Dr. Nelson is on the advisory board for the National Center for School Crisis and Bereavement.
MD: University of Oklahoma Health Sciences Center, Oklahoma City, OK, 1985.
Residency: Medical Center Hospital / Audie Murphy, San Antonio, TX, 1987.
Fellowship: San Antonio Children's Center, Southwest Neuropsychiatric Institute, San Antonio, TX, 1989.
Certification: General Psychiatry, 1992; Child and Adolescent Psychiatry, 1994.
Elizabeth K. Schorry, MD Director, Neurofibromatosis Clinic 513-636-0121 email@example.com
Director, Neurofibromatosis Clinic
Director, Adult Neurofibromatosis Clinic
Genetic disorders; congenital anomalies; neurofibromatosis; tuberous sclerosis; bone disease in neurofibromatosis; Ehlers-Danlos syndrome
Elizabeth Schorry, MD, received her undergraduate degree at the University of Cincinnati and her MD at the University of Michigan in Ann Arbor, Michigan.
Dr. Schorry completed a residency in pediatrics and a fellowship in medical genetics at Cincinnati Children's Hospital Medical Center. She has been a faculty member in the Division of Human Genetics at Cincinnati Children's since 1988.
Dr. Schorry provides medical management, genetic assessment and genetic counseling for children with a wide range of genetic disorders and congenital anomalies. She has a special interest in neurofibromatosis and tuberous sclerosis.
BS: Biology, University of Cincinnati, Cincinnati, OH, 1977.
MD: University of Michigan, Ann Arbor, MI, 1982.
Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH, 1982-1985.
Fellowship: Genetics, Children's Hospital Medical Center, Cincinnati, OH, 1985-1988.
Certification: American Board of Pediatrics, 1987; Clinical Genetics, American Board of Medical Genetics, 1987.
Prada CE, Zarate YA, Hagenbuch S, Lovell A, Schorry EK, Hopkin RJ. Lethal presentation of neurofibromatosis and Noonan syndrome. Am J Med Genet A. 2011 Jun;155A(6):1360-6.
Rieley MB, Stevenson DA, Viskochil DH, Tinkle BT, Martin LJ, Schorry EK. Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet A. 2011 Mar;155A(3):478-85.
Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG. Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A. 2011 Feb;155(2):307-21.
Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010 Oct 15;16(20):5048-57.
Stevenson DA, Viskochil DH, Carey JC, Slater H, Murray M, Sheng X, D'Astous J, Hanson H, Schorry E, Moyer-Mileur LJ. Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography. Bone. 2009 Apr;44(4):585-9.
Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, Crawford AH, Friedman JM, Little D, Peltonen J, Carey JC, Feldman D, Yu X, Armstrong L, Birch P, Kendler DL, Mundlos S, Yang FC, Agiostratidou G, Hunter-Schaedle K, Stevenson DA. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009 Oct;149A(10):2327-38.
Schorry EK, Keddache M, Lanphear N, Rubinstein JH, Srodulski S, Fletcher D, Blough-Pfau RI, Grabowski GA. Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am J Med Genet A. 2008 Oct 1;146A(19):2512-9.
Crawford AH, Parikh S, Schorry EK, Von Stein D. The immature spine in type-1 neurofibromatosis. J Bone Joint Surg Am. 2007 Feb;89 Suppl 1:123-42.
Zarate YA, Kogan JM, Schorry EK, Smolarek TA, Hopkin RJ. A new case of de novo 11q duplication in a patient with normal development and intelligence and review of the literature. Am J Med Genet A. 2007 Feb 1;143(3):265-70.
Tinkle BT, Miller E, Schorry EK. Gene symbol: COL1A2. Disease: osteogenesis imperfecta type II. Hum Genet. 2006 Jul;119(6):677.
Brian J. Siroky, PhD Member, Division of Nephrology 513-636-4497 firstname.lastname@example.org
Member, Division of Nephrology
Instructor, UC Department of Pediatrics
Tuberous sclerosis complex; polycystic kidney disease; primary cilia
BS: Western Kentucky University, Bowling Green, KY, 1999.
PhD: University of Alabama at Birmingham, Birmingham, AL, 2006.
Postdoctoral Fellowship: Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2006–2010.
Karen D. Agricola, MSN, APRN, FNP-BC Advanced Practice Registered Nurse, Tuberous Sclerosis 513-636-4222 TSclinic@cchmc.org
Advanced Practice Registered Nurse, Tuberous Sclerosis
MSN-FNP: University of Kentucky, Ky, 1990.Internship: Family Practice, Portland Family Health Center, Louisville, Ky, 1990.
Certification: Family Nurse Practitioner since 1990.
Jennifer E. Glass, LGC
Genetic Counselor II, Division of Human Genetics 513-803-3264 email@example.com
Cindy Tudor, RN, APRN, CNP Nurse Practitioner, Division of Neurology 513-636-4222 firstname.lastname@example.org
Nurse Practitioner, Division of Neurology
Linda L. Wallace, LISW
Social Worker, Division of Social Services 513-636-9096 email@example.com
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center